Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. UroGen Pharma Ltd.
  6. Summary
    URGN   IL0011407140

UROGEN PHARMA LTD.

(URGN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2021 10/12/2021 10/13/2021 10/14/2021 10/15/2021 Date
15.9(c) 16.94(c) 17.24(c) 17.15(c) 17.02(c) Last
33 959 59 399 38 379 48 448 40 472 Volume
+0.13% +6.54% +1.77% -0.52% -0.76% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 54,5 M - -
Net income 2021 -114 M - -
Net cash position 2021 28,6 M - -
P/E ratio 2021 -3,47x
Yield 2021 -
Sales 2022 105 M - -
Net income 2022 -88,7 M - -
Net cash position 2022 122 M - -
P/E ratio 2022 -5,04x
Yield 2022 -
Capitalization 381 M 381 M -
EV / Sales 2021 6,46x
EV / Sales 2022 2,47x
Nbr of Employees 190
Free-Float 89,7%
More Financials
Company
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using... 
More about the company
Ratings of UroGen Pharma Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about UROGEN PHARMA LTD.
10/06UROGEN PHARMA : The Journal of Urology Publishes Results of UroGen Pharma's Phase 2b Study..
AQ
10/05UROGEN PHARMA : The Journal of Urology Publishes Results of UroGen Pharma's Phase 2b Study..
BU
10/05The Journal of Urology Publishes Results of UroGen Pharma Ltd.'s Phase 2B Study of UGN-..
CI
09/23UROGEN PHARMA : to Present at the 2021 Cantor Virtual Global Healthcare Conference
BU
09/13UROGEN PHARMA : to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
AQ
09/13UROGEN PHARMA LTD. : Other Events (form 8-K)
AQ
09/13UROGEN PHARMA : Presents Data Showcasing Novel Clinical Data at 2021 American Urological A..
BU
09/13UroGen Pharma Ltd. Announces Final Data from Two Key Trials, Evaluating the Safety and ..
CI
09/10UROGEN PHARMA : to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
BU
09/06UROGEN PHARMA : Announces Inducement Grant Under Nasdaq Listing Rule 5635(4)
AQ
09/03UROGEN PHARMA : Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BU
08/05UROGEN PHARMA : Reports Second Quarter 2021 Financial Results and Recent Corporate Develop..
AQ
08/04UROGEN PHARMA : Reports Second Quarter 2021 Financial Results and Recent Corporate Develop..
PU
08/04UROGEN PHARMA LTD. : Results of Operations and Financial Condition, Financial Statements a..
AQ
08/04UROGEN PHARMA : Management's Discussion and Analysis of Financial Condition and Results of..
AQ
More news
News in other languages on UROGEN PHARMA LTD.

- No features available -

More news
Analyst Recommendations on UROGEN PHARMA LTD.
More recommendations
Chart UROGEN PHARMA LTD.
Duration : Period :
UroGen Pharma Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends UROGEN PHARMA LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 17,02 $
Average target price 42,60 $
Spread / Average Target 150%
EPS Revisions
Managers and Directors
Elizabeth Barrett President, Chief Executive Officer & Director
Molly Henderson Chief Financial & Accounting Officer
Arie S. Belldegrun Chairman
Moran Mieron Director-Research & Pre-Clinical Affairs
Mark P. Schoenberg Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
UROGEN PHARMA LTD.-5.55%381
GILEAD SCIENCES, INC.16.08%84 795
WUXI APPTEC CO., LTD.29.45%66 184
BIONTECH SE203.83%59 820
REGENERON PHARMACEUTICALS14.52%57 519
VERTEX PHARMACEUTICALS-23.09%47 156